Who are MCI-196's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ferrlecit, Renvela, Lanthanum Carbonate Chewable Tablet, Sucroferric Oxyhydroxide Chewable Tablet, Ferric Citrate 1 GM Oral Tablet [AURYXIA], Calcium acetate (PhosLo® ).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mci-196.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

MCI-196 — Competitive Intelligence Brief

MCI-196 (MCI-196) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phosphate binder. Area: Nephrology / Chronic Kidney Disease.

phase 3 Phosphate binder Dietary and secreted phosphate (non-selective binding) Nephrology / Chronic Kidney Disease Small molecule Live · refreshed every 30 min

Target snapshot

MCI-196 (MCI-196) — Tanabe Pharma Corporation. MCI-196 is a phosphate binder that reduces serum phosphate levels by binding phosphate in the gastrointestinal tract.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MCI-196 TARGET	MCI-196	Tanabe Pharma Corporation	phase 3	Phosphate binder	Dietary and secreted phosphate (non-selective binding)
Ferrlecit	sucroferric oxyhydroxide	Vifor Fresenius	marketed	Phosphate Binder [EPC]		2013-01-01
Renvela	SEVELAMER CARBONATE	Sanofi	marketed	Phosphate Binder		2007-01-01
Lanthanum Carbonate Chewable Tablet	Lanthanum Carbonate Chewable Tablet	SIGA Technologies	marketed	Phosphate binder	Dietary phosphate (non-receptor mechanism)
Sucroferric Oxyhydroxide Chewable Tablet	Sucroferric Oxyhydroxide Chewable Tablet	University of Colorado, Denver	marketed	Phosphate binder	Dietary phosphate (non-receptor mechanism)
Ferric Citrate 1 GM Oral Tablet [AURYXIA]	Ferric Citrate 1 GM Oral Tablet [AURYXIA]	USRC Kidney Research	phase 3	Phosphate binder	Dietary phosphate (non-receptor mechanism)
Calcium acetate (PhosLo® )	Calcium acetate (PhosLo® )	Genzyme, a Sanofi Company	phase 3	Phosphate binder	Dietary phosphate (non-receptor mechanism)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-11-13 — Ferrlecit · 10682376 · US
2028-11-13 — Ferrlecit · 10933090 · US
2028-11-13 — Ferrlecit · 11013762 · US
2028-11-13 — Ferrlecit · 10925896 · US
2028-11-13 — Ferrlecit · 10695367 · US
2028-11-13 — Ferrlecit · 11013761 · US
2028-11-13 — Ferrlecit · 10925897 · US
2029-05-13 — Ferrlecit · 10925896*PED · US
2029-05-13 — Ferrlecit · 10682376*PED · US
2029-05-13 — Ferrlecit · 11013762*PED · US
2029-05-13 — Ferrlecit · 10695367*PED · US
2029-05-13 — Ferrlecit · 10925897*PED · US
2029-05-13 — Ferrlecit · 10933090*PED · US
2029-05-13 — Ferrlecit · 11013761*PED · US
2030-01-23 — Ferrlecit · 9561251 · US
2030-07-23 — Ferrlecit · 9561251*PED · US
2034-11-26 — Ferrlecit · 10624855 · US
2034-11-26 — Ferrlecit · 11234938 · US
2034-11-26 — Ferrlecit · 11446252 · US
2035-05-26 — Ferrlecit · 11446252*PED · US
2035-05-26 — Ferrlecit · 10624855*PED · US
2035-05-26 — Ferrlecit · 11234938*PED · US

Sponsor landscape (Phosphate binder class)

Genzyme, a Sanofi Company · 1 drug in this class
SIGA Technologies · 1 drug in this class
Sanofi · 1 drug in this class
Shire · 1 drug in this class
Tanabe Pharma Corporation · 1 drug in this class
USRC Kidney Research · 1 drug in this class
University of Colorado, Denver · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MCI-196 — Competitive Intelligence Brief. https://druglandscape.com/ci/mci-196. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab